2 December 2025
Notification of trade – primary insider/close associate
2 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company“) on 14 November 2025 and on 17 November 2025, regarding the commencement of the subscription period in the fully underwritten rights issue of 260,000,000 new shares in the Company (the “Rights Issue“) and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of the Company. Further reference is made to the stock exchange announcement published by the Company on 2 December 2025, regarding the final result of the Rights Issue and the allocation of the new shares.
Certain primary insiders and close associates have been allocated new shares:
- Charles Gillies O’Bryan-Tear, chairperson of the board of directors of the Company, has been allocated 2,000,000 shares.
- Teakay Invest AS, a company closely associated to Ingrid Teigland Akay, member of the Company’s board of directors, has been allocated 664,551 shares.
- Abakus Invest AS, a company closely associated to Øystein Soug, Chief Executive Officer of the Company, has been allocated 757,206 shares.
- Anne Cecilie Alvik, Head of Quality Assurance, has been allocated 40,000 shares.
- Hadean Capital I AS, a company closely associated to Ingrid Teigland Akay, member of the Company’s board of directors, has been allocated 17,787,881 shares.
- HVentures Capital I AB, a company closely associated to Ingrid Teigland Akay, member of the Company’s board of directors, has been allocated 8,068,142 shares.
- Olav Hellebø, member of the Company’s board of directors, has been allocated 200,000 shares.
- Gro E. Hjellum, Chief Operating Officer, has been allocated 100,000 shares.
- Itza AS, a company closely associated to Tore Kvam, Chief Financial Officer, has been allocated 454,324 shares.
- Hadean Growth Fund I AS, a company closely associated to Ingrid Teigland Akay, member of the Company’s board of directors, has been allocated 8,666,991 shares.
Please refer to the attached notifications of trade for further information.
Issuance and delivery of the new shares is subject to the extraordinary general meeting of the Company to be held on 5 December 2025 approving the required share capital reduction to reduce the nominal value of the Company’s shares (as further described in section 7.4.3 of the prospectus prepared by the Company), any other resolutions required to complete the Rights Issue, and the timely payment for the new shares subscribed for and allocated.
This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
